Pure Global AI
NCT06314542Recruiting

Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data

Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria on the Risk-benefit Profile of Drugs for Lung Cancer Based on Real-world Data
Cancer Institute and Hospital, Chinese Academy of Medical SciencesClinicalTrials.govother
Verified
Study focus
Disease/Condition
Lung Cancer
Drug/Device/Intervention
relaxing eligibility criteria
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2013
End date
Jun 30, 2026
Enrollment
50000 participants
Primary outcome

Scale of eligibility criteria

Summary

Eligibility criteria for cancer drug trials are generally too stringent, leading to key
 issues such as low enrolment rates and lack of population diversity. In order to evaluate the
 REC of NSCLC drug trials, this study will use deep learning methods to construct a structured
 real-world database of NSCLC across dimensions, and quantitatively assess the independent
 contribution of changes in each eligibility criterion to patient numbers, clinical efficacy
 and safety.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm of bronchus and lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm: Overlapping lesion of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06314542
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06314542 through Pure Global AI's free database. This phase not specified trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 50000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.